05:14 PM EDT, 04/02/2024 (MT Newswires) -- Sight Sciences ( SGHT ) said late Tuesday that results from studies of two of its glaucoma and dry eye technologies will be presented at this year's meeting of the American Society of Cataract and Refractive Surgery, which will take place from April 5 to April 8 in Boston.

The results showed the "long-term efficacy of the OMNI Surgical System for primary open-angle glaucoma" and also back the use of TearCare as "a primary treatment for dry eye disease," the company said.

Sight Sciences ( SGHT ) shares were rising 25% in recent after-hours trading.

Price: 6.8, Change: +1.36, Percent Change: +25